

External Evaluation | FY2023 Archive

| External evaluation on Sustainability

FTSE Blossom Japan Index*



FTSE Blossom
Japan Index

The FTSE Blossom Japan Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

FTSE Blossom Japan Sector Relative Index*



FTSE Blossom
Japan Sector
Relative Index


The FTSE Blossom Japan Sector Relative Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices in each sector. Sumitomo Pharma has been continuously included as a constituent in the Index since 2022 when the Index was launched.

MSCI Nihonkabu ESG Select Leaders Index*

2024 CONSTITUENT MSCI NIHONKABU
ESG SELECT LEADERS INDEX

Among the stocks that make up the MSCI Nihonkabu IMI Index, the MSCI Nihonkabu ESG Select Leaders Index aims to represent the performance of companies that are leading within their GICS[®] sector groups in terms of ESG evaluations while also meeting certain quality factor criteria. Sumitomo Pharma has been included as a constituent in the index since 2024 when the Index was launched.

S&P/JPX Carbon Efficient Index*



The S&P/JPX Carbon Efficient Index is an ESG index jointly designed by S&P Dow Jones Indices and Japan Exchange Group. This index comprises companies included in the Tokyo Stock Price Index (TOPIX), and the weight of constituent is determined by carbon efficiency (Carbon emissions per unit of revenue) and the disclosure status of environmental information. Sumitomo Pharma has been included as a constituent in the Index since 2018 when the Index was launched.

Morningstar Japan ex-REIT Gender Diversity Tilt Index*

MORNINGSTAR GenDi J

Japan ex-REIT Gender Diversity
Tilt Index

TOP CONSTITUENT 2025

Built with the data and scoring methodology of Equileap (Netherlands), the Morningstar (U.S.) Gender Diversity Indexes are designed to emphasize the stocks of companies that have strong gender diversity policies embedded in their corporate culture and that ensure equal opportunities to employees, irrespective of their gender. This index was newly adopted by GPIF from March 2023. Sumitomo Pharma has been included in the constituent stocks since its establishment in 2023, and has been certified as the highest “Group 1.”

SOMPO Sustainability Index



SOMPO Sustainability index is created by the SOMPO Asset Management, and is used in SRI (socially responsible investment) fund for pension funds or institutional investors to invest widely in companies with the high ESG (environment, society, governance) evaluation ratings. Sumitomo Pharma has been continuously included as a constituent in the Index since 2012 when the Index was launched.

CDP



CDP is a global non-profit that runs the world's environmental disclosure system for companies, cities, states and regions. Sumitomo Pharma has been selected by CDP as the highest A-List company in the category of "climate change" in CDP 2024, in recognition of its efforts and measures against climate change.

*We have been selected for five inclusions in a constituent of the ESG indexes that cover Japanese stocks adopted by the Government Pension Investment Fund (GPIF) (as of the end of August 2024).

(DISCLAIMER)

- THE INCLUSION OF Sumitomo Pharma Co., Ltd. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF Sumitomo Pharma Co., Ltd. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.
- Morningstar, Inc., and/or one of its affiliated companies (individually and collectively, "Morningstar") has authorized Sumitomo Pharma Co., Ltd. to use of the Morningstar[®] Japan ex-REIT Gender Diversity Tilt Logo ("Logo") to reflect the fact that, for the designated ranking year, Sumitomo Pharma Co., Ltd. ranks within the top group of companies comprising the Morningstar[®] Japan ex-REIT Gender Diversity Tilt IndexSM ("Index") on the issue of gender diversity in the workplace. Morningstar is making the Logo available for use by Sumitomo Pharma Co., Ltd. for informational purposes. Sumitomo Pharma Co., Ltd. use of the Logo should not be construed as an endorsement by Morningstar of Sumitomo Pharma Co., Ltd. or as a recommendation, offer or solicitation to purchase, sell or underwrite any security associated with Sumitomo Pharma Co., Ltd. The Index is designed to reflect gender diversity in the workplace in Japan, but Morningstar does not guarantee the accuracy, completeness or timeliness of the Index or any data included in it. Morningstar makes no express or implied warranties regarding the Index or the Logo, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the Index, any data included in it or the Logo. Without limiting any of the foregoing, in no event shall Morningstar or any of its third party content providers have any liability for any damages (whether direct or indirect), arising from any party's use or reliance on the Index or the Logo, even if Morningstar is notified of the possibility of such damages. The Morningstar name, Index name and the Logo are the trademarks or services marks of Morningstar, Inc. Past performance is no guarantee of future results.